Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

  • Takashi Kadowaki, Kazuoki Kondo, Noriyuki Sasaki, Kyoko Miyayama, Shoko Yokota, Ryuji Terata, Maki Gouda
  • Expert Opinion on Pharmacotherapy, August 2017, Taylor & Francis
  • DOI: 10.1080/14656566.2017.1359259

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/14656566.2017.1359259